The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Insights into a Phase I/II study assessing golidocitinib in PTCL
Won-Seog Kim
• 11 Jun 2022
Won Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, briefly discusses the findings of a Phase I/II study evaluating the efficacy of golidocitinib in patients with peripheral T-cell lymphoma (PTCL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
